Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in AustraliaAvecho to receive ...

CACI's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting ...

This summer is likely to be an emotional time for many in Ulverston.

An Australian biotech minnow wants to become the first company globally to register an over-the-counter cannabidiol product ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Emasan AG, a subsidiary of the Sandoz Family Foundation, has initiated a public offering of approximately 26.5 million shares ...

Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis ...

Southeast Asia stands at a pivotal moment in healthcare development. While the region represents 8.5 per cent of the world’s ...

(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.

The Ferrari deal is expected to be the largest of a clutch of block trades this week, including a Sfr2.6bn (€2.8bn) block in ...